CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen
Abstract
:1. Introduction
2. Results and Discussion
2.1. Results
Characteristics | No. of Pts | High CES2 Expression 2 + 3 No. Cases (%) | High ABCG2 Expression 2 No. Cases (%) | High TS Expression No. Cases (%) | High Topo-I Expression No. Cases (%) | ||||
---|---|---|---|---|---|---|---|---|---|
Gender | |||||||||
Male | 33 | 23 | (70) * | 18 | (55) | 14 | (42) | 19 | (58) |
Female | 25 | 9 | (36) * | 14 | (56) | 7 | (28) | 9 | (36) |
Tumor site | |||||||||
Colon | 24 | 12 | (50) | 15 | (63) | 9 | (38) | 12 | (50) |
Rectum | 34 | 20 | (59) | 17 | (50) | 12 | (35) | 16 | (47) |
Stage | |||||||||
Primary | 38 | 20 | (53) | 23 | (61) | 13 | (34) | 19 | (50) |
Recurrent | 20 | 11 | (55) | 9 | (45) | 7 | (35) | 8 | (40) |
Site | |||||||||
Liver | 20 | 10 | (50) | 8 | (40) | 5 | (25) | 10 | (50) |
Other | 38 | 22 | (58) | 24 | (63) | 16 | (42) | 18 | (47) |
ECOG PS | |||||||||
0 | 32 | 19 | (59) | 20 | (63) | 12 | (38) | 19 | (59) |
1 + 2 | 25 | 13 | (52) | 12 | (48) | 9 | (36) | 8 | (32) |
Clinical Response | |||||||||
CR + PR | 20 | 11 | (55) | 11 | (55) | 6 | (30) | 9 | (45) |
SD | 16 | 9 | (56) | 10 | (63) | 7 | (44) | 6 | (38) |
PD | 18 | 9 | (50) | 8 | (44) | 5 | (28) | 10 | (56) |
Characteristics | No. of Pts | Clinical Responses (%) (CR + PR) | Median TTP Months (95% CI) | p-Value | |
---|---|---|---|---|---|
CES2 | |||||
0 + 1 | 24 | 29 | 11 | (8–14) | 0.24 |
2 + 3 | 29 | 38 | 9 | (7–11) | |
ABCG2 | |||||
0 + 1 | 22 | 27 | 10 | (7–13) | 0.62 |
2 | 29 | 38 | 9 | (3–15) | |
TS * | |||||
Low | 32 | 38 | 11 | (9–13) | 0.005 ** |
High | 19 | 32 | 6 | (4–8) | |
Topo-I * | |||||
Low | 28 | 32 | 10 | (8–12) | 0.58 |
High | 24 | 38 | 9 | (6–12) |
Characteristics | OS Hazards Ratio (95% CI) | p-Value |
---|---|---|
CES2 (2 + 3 vs. 0 + 1) | 0.74 (0.26–2.13) | 0.58 |
ABCG2 (2 vs. 0 + 1) | 0.54 (0.19–1.54) | 0.25 |
TS (high vs. low) * | 3.89 (1.26–12.04) | 0.01 |
2.2. Discussion
3. Experimental Section
3.1. Patients
3.2. Immunohistochemistry (IHC)
3.3. Statistical Analysis
4. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Uchida, K.; Otake, K.; Tanaka, K.; Hashimoto, K.; Saigusa, S.; Matsushita, K.; Koike, Y.; Inoue, M.; Ueeda, M.; Okugawa, Y.; et al. Clinical implications of CES2 RNA expression in neuroblastoma. J. Pediatr. Surg. 2013, 48, 502–509. [Google Scholar]
- Marsh, S.; Hoskins, J.M. Irinotecan pharmacogenomics. Pharmacogenomics 2010, 11, 1003–1010. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Shannon, W.D.; Duncan, J.; Scheffer, G.L.; Scheper, R.J.; McLeod, H.L. Expression of drug pathway proteins is independent of tumour type. J. Pathol. 2006, 209, 213–219. [Google Scholar] [CrossRef] [PubMed]
- Satoh, T.; Hosokawa, M.; Atsumi, R.; Suzuki, W.; Hakusui, H.; Nagai, E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol. Pharm. Bull. 1994, 17, 662–664. [Google Scholar] [CrossRef] [PubMed]
- Chu, X.Y.; Kato, Y.; Sugiyama, Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab. Dispos. 1999, 27, 440–441. [Google Scholar] [PubMed]
- Tesauro, C.; Morozzo della Rocca, B.; Ottaviani, A.; Coletta, A.; Zuccaro, L.; Arno, B.; D’Annessa, I.; Fiorani, P.; Desideri, A. Molecular mechanism of the camptothecinresistance of Glu710Gly topoisomerase IB mutantanalyzed in vitro and in silico. Mol. Cancer 2013, 12, 100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paradiso, A.; Xu, J.; Mangia, A.; Chiriatti, A.; Simone, G.; Zito, A.; Montemurro, S.; Giuliani, F.; Maiello, E.; Colucci, G. Topoisomerase-I, thymidylatesynthaseprimarytumour expression and clinicalefficacy of 5-FU/CPT-11 chemotherapy in advancedcolorectal cancer patients. Int. J. Cancer 2004, 111, 252–258. [Google Scholar] [CrossRef] [PubMed]
- Xiao, D.; Yang, D.; Guo, L.; Lu, W.; Charpentier, M.; Yan, B. Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidineprodrug. Br. J. Pharmacol. 2013, 168, 1989–1999. [Google Scholar] [CrossRef] [PubMed]
- Sanghani, S.P.; Quinney, S.K.; Fredenburg, T.B.; Sun, Z.; Davis, W.I.; Murry, D.J.; Cummings, O.W.; Seitz, D.E.; Bosron, W.F. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Clin. Cancer Res. 2003, 9, 4983–4991. [Google Scholar] [PubMed]
- Schiel, M.A.; Green, S.L.; Davis, W.I.; Sanghani, P.C.; Bosron, W.F.; Sanghani, S.P. Expression and characterization of a human carboxylesterase 2 splice variant. J. Pharmacol. Exp. Ther. 2007, 323, 94–101. [Google Scholar] [CrossRef] [PubMed]
- Xie, F.W.; Peng, Y.H.; Chen, X.; Li, J.; Wang, W.W.; Yu, Z.Y.; Ouyang, X.N. Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation. Neoplasma 2014, 61, 99–109. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Q.; Li, K.; Xu, J.H.; Zhao, C.G.; Gao, Q.; Wu, B.; Liu, X.Y. Role of ABCG2 expression driven by cisplatin in platinum-containing chemotherapy for gastric cancer. World J. Gastroenterol. 2013, 19, 6630–6636. [Google Scholar] [CrossRef] [PubMed]
- Maithel, S.K.; Gönen, M.; Ito, H.; Dematteo, R.P.; Allen, P.J.; Fong, Y.; Blumgart, L.H.; Jarnagin, W.R.; D’Angelica, M.I. Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery 2012, 151, 162–170. [Google Scholar] [CrossRef] [PubMed]
- Chiorean, E.G.; Sanghani, S.; Schiel, M.A.; Yu, M.; Burns, M.; Tong, Y.; Hinkle, D.T.; Coleman, N.; Robb, B.; LeBlanc, J.; et al. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03–53. Cancer Chemother. Pharmacol. 2012, 70, 25–32. [Google Scholar] [CrossRef] [PubMed]
- Shen, B.; Dong, P.; Li, D.; Gao, S. Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines. Exp. Ther. Med. 2011, 2, 1151–1157. [Google Scholar] [PubMed]
- Wang, X.; Xia, B.; Liang, Y.; Peng, L.; Wang, Z.; Zhuo, J.; Wang, W.; Jiang, B. Membranous ABCG2 expression in colorectal cancer independently correlates with shortened patient survival. Cancer Biomark. 2013, 13, 81–88. [Google Scholar] [PubMed]
- Kadota, K.; Huang, C.L.; Liu, D.; Yokomise, H.; Haba, R.; Wada, H. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors. Int. J. Oncol. 2011, 38, 355–363. [Google Scholar] [PubMed]
- Popat, S.; Matakidou, A.; Houlston, R.S. Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J. Clin. Oncol. 2004, 22, 529–536. [Google Scholar] [CrossRef] [PubMed]
- Azzoni, C.; Bottarelli, L.; Cecchini, S.; Ziccarelli, A.; Campanini, N.; Bordi, C.; Sarli, L.; Silini, E.M. Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: Associations with clinicopathological and molecular features. Pathol. Res. Pract. 2014, 210, 111–117. [Google Scholar] [PubMed]
- Tsourouflis, G.; Theocharis, S.E.; Sampani, A.; Giagini, A.; Kostakis, A.; Kouraklis, G. Prognostic and predictive value of thymidylate synthase expression in colon cancer. Dig. Dis. Sci. 2008, 53, 1289–1296. [Google Scholar] [CrossRef] [PubMed]
- Lurje, G.; Manegold, P.C.; Ning, Y.; Pohl, A.; Zhang, W.; Lenz, H.J. Thymidylate synthase gene variations: Predictive and prognostic markers. Mol. Cancer Ther. 2009, 8, 1000–1007. [Google Scholar] [CrossRef] [PubMed]
- Maiello, E.; Gebbia, V.; Giuliani, F.; Paoletti, G.; Gebbia, N.; Cigolari, S.; Fortunato, S.; Pedicini, T.; Borsellino, N.; Lopez, M.; et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: A multicenter randomised phase II study of the Southern Italy Oncology Group. Ann. Oncol. 2000, 11, 1045–1051. [Google Scholar] [CrossRef] [PubMed]
- Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; Gwyther, S.; Mooney, M.; et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247. [Google Scholar]
- Paradiso, A.; Scarpi, E.; Malfettone, A.; Addati, T.; Giotta, F.; Simone, G.; Amadori, D.; Mangia, A. Nuclear NHERF1 expression as a prognostic marker in breast cancer. Cell. Death Dis. 2013, 4, e904. [Google Scholar] [CrossRef] [PubMed]
- Xu, G.; Zhang, W.; Ma, M.K.; McLeod, H.L. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin. Cancer Res. 2002, 8, 2605–2611. [Google Scholar] [PubMed]
- Diestra, J.E.; Scheffer, G.L.; Catala, I.; Maliepaard, M.; Schellens, J.H.; Scheper, R.J.; Germa-Lluch, J.R.; Izquierdo, M.A. Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J. Pathol. 2002, 198, 213–219. [Google Scholar] [CrossRef] [PubMed]
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Silvestris, N.; Simone, G.; Partipilo, G.; Scarpi, E.; Lorusso, V.; Brunetti, A.E.; Maiello, E.; Paradiso, A.; Mangia, A. CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen. Int. J. Mol. Sci. 2014, 15, 15767-15777. https://doi.org/10.3390/ijms150915767
Silvestris N, Simone G, Partipilo G, Scarpi E, Lorusso V, Brunetti AE, Maiello E, Paradiso A, Mangia A. CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen. International Journal of Molecular Sciences. 2014; 15(9):15767-15777. https://doi.org/10.3390/ijms150915767
Chicago/Turabian StyleSilvestris, Nicola, Giovanni Simone, Giulia Partipilo, Emanuela Scarpi, Vito Lorusso, Anna Elisabetta Brunetti, Evaristo Maiello, Angelo Paradiso, and Anita Mangia. 2014. "CES2, ABCG2, TS and Topo-I Primary and Synchronous Metastasis Expression and Clinical Outcome in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Regimen" International Journal of Molecular Sciences 15, no. 9: 15767-15777. https://doi.org/10.3390/ijms150915767